Publications by authors named "Lindsey Finney"

Claim this Profile
A
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma.
Gerald S Falchook, James D Battiste, Amandeep Kalra, Mythili Shastry, Lindsey Finney

Neurooncol Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A Yardley, Robyn R Young, Kerin B Adelson, Andrea L Silber, Jose E Najera, Lindsey Finney

Clin Breast Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
Denise A Yardley, Dianna Shipley, John Zubkus, Gail L Wright, Patrick J Ward, Lindsey Finney

Clin Breast Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabazitaxel Plus Lapatinib as Therapy for HER2 Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
Denise A Yardley, Lowell L Hart, Patrick J Ward, Gail L Wright, Mythili Shastry, Lindsey Finney

Clin Breast Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
David R Spigel, Howard A Burris, F Anthony Greco, Kent C Shih, Victor G Gian, Lindsey Finney

Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
Denise A Yardley, John D Zubkus, Janice F Eakle, Rebecca G Bechhold, Lindsey Finney

Clin Breast Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
John D Hainsworth, Dana S Thompson, John A Bismayer, Victor G Gian, William M Merritt, Lindsey H Finney

Cancer Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Johanna C Bendell, Carla Kurkjian, Jeffrey R Infante, Todd M Bauer, Howard A Burris, Lindsey H Finney

Invest New Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis